- Price
- $13.82
- Day
- -3.56%
- Mkt Cap
- $237.67M
- 52W Range
- $5.78 – $19.40
- Volume
- 2.25M
- Beta
- 0.91
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
Read full article
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read full article